X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs TEVA PHARMA (Israel) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   TEVA PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
TEVA PHARMA
Dec-13
SANOFI INDIA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,8402,893-   
Low Rs4,6302,514-   
Sales per share (Unadj.) Rs1,203.11,660.6-  
Earnings per share (Unadj.) Rs165.3103.7-  
Cash flow per share (Unadj.) Rs209.9238.0-  
Dividends per share (Unadj.) Rs84.0090.81-  
Dividend yield (eoy) %1.53.4 43.6%  
Book value per share (Unadj.) Rs963.61,844.6-  
Shares outstanding (eoy) m23.03848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.81.6 292.8%   
Avg P/E ratio x34.726.1 133.2%  
P/CF ratio (eoy) x27.311.4 240.5%  
Price / Book Value ratio x6.01.5 406.1%  
Dividend payout %50.887.5 58.1%   
Avg Mkt Cap Rs m132,0782,292,551 5.8%   
No. of employees `0003.344.9 7.3%   
Total wages/salary Rs m4,0680-   
Avg. sales/employee Rs Th8,393.831,330.9 26.8%   
Avg. wages/employee Rs Th1,232.40-   
Avg. net profit/employee Rs Th1,153.01,957.2 58.9%   
INCOME DATA
Net Sales Rs m27,7081,408,166 2.0%  
Other income Rs m8970-   
Total revenues Rs m28,6051,408,166 2.0%   
Gross profit Rs m6,235385,627 1.6%  
Depreciation Rs m1,027113,823 0.9%   
Interest Rs m727,659 0.0%   
Profit before tax Rs m6,098244,145 2.5%   
Minority Interest Rs m01,109 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-160,268 0.0%   
Tax Rs m2,292-2,981 -76.9%   
Profit after tax Rs m3,80687,967 4.3%  
Gross profit margin %22.527.4 82.2%  
Effective tax rate %37.6-1.2 -3,078.6%   
Net profit margin %13.76.2 219.9%  
BALANCE SHEET DATA
Current assets Rs m15,922951,070 1.7%   
Current liabilities Rs m6,235829,414 0.8%   
Net working cap to sales %35.08.6 404.7%  
Current ratio x2.61.1 222.7%  
Inventory Days Days6491 70.1%  
Debtors Days Days2196 21.8%  
Net fixed assets Rs m7,539459,938 1.6%   
Share capital Rs m2303,466 6.6%   
"Free" reserves Rs m21,9620-   
Net worth Rs m22,1921,564,206 1.4%   
Long term debt Rs m0720,027 0.0%   
Total assets Rs m29,8393,218,112 0.9%  
Interest coverage x872.19.8 8,874.9%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.4 212.2%   
Return on assets %12.83.6 355.7%  
Return on equity %17.25.6 305.0%  
Return on capital %27.54.9 557.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m4420-   
CASH FLOW
From Operations Rs m3,739224,389 1.7%  
From Investments Rs m-731-79,510 0.9%  
From Financial Activity Rs m-1,972-269,170 0.7%  
Net Cashflow Rs m1,036-124,291 -0.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 69.32 Rs / USD

Compare SANOFI INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare SANOFI INDIA With: AUROBINDO PHARMA  WOCKHARDT  SHASUN PHARMA  DR. DATSONS LABS  DIVIS LABORATORIES  



Today's Market

Sensex Opens Marginally Higher; Capital Goods & Power Stocks Lead(09:30 am)

Asian share markets slipped on Wednesday and the dollar pulled back from three-month lows after Federal Reserve officials tempered expectations in the markets for aggressive monetary easing.

Related Views On News

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)

Jun 19, 2019

This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 26, 2019 10:05 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - FRESENIUS KABI ONCO. COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS